FILIP1L Antibody
Description
What is FILIP1L Antibody?
FILIP1L antibodies are immunoreagents designed to bind specifically to the FILIP1L protein, a regulator of the WNT/β-catenin pathway and epithelial-to-mesenchymal transition (EMT). FILIP1L acts as a tumor suppressor by promoting β-catenin degradation, inhibiting metastasis, and enhancing chemosensitivity in cancers such as ovarian and colorectal carcinomas . Antibodies targeting FILIP1L are widely used in techniques like immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to study its expression and function.
Applications of FILIP1L Antibodies in Research
FILIP1L antibodies are pivotal in elucidating the protein’s role in cancer progression and therapeutic response. Below are key applications supported by experimental data:
Prognostic Marker in Ovarian Cancer
-
Low FILIP1L expression correlates with advanced tumor stage, chemoresistance, and poor survival .
-
Antibody-based IHC on 369 ovarian samples confirmed FILIP1L’s inverse relationship with β-catenin and EMT markers (e.g., SNAIL, SLUG) .
Suppressor of Colorectal Cancer (CRC) Progression
-
FILIP1L knockdown in CRC cells (e.g., COLO205) enhances migration, invasion, and angiogenesis, while overexpression (e.g., HCT116) induces apoptosis and cell cycle arrest .
-
IHC of patient tissues revealed FILIP1L’s association with reduced tumor size, lymph node metastasis, and improved survival .
Regulation of Angiogenesis
-
Overexpression of FILIP1L in endothelial cells inhibits proliferation, migration, and tumor neovascularization .
-
Truncated FILIP1L mutants (e.g., FILIP1LΔC103) suppress melanoma growth by targeting tumor vasculature .
Mechanism of Action
-
FILIP1L promotes β-catenin phosphorylation and proteasomal degradation, thereby inhibiting WNT target genes (e.g., MMP3, MMP9) and EMT .
-
In CRC, FILIP1L inactivation elevates Akt/GSK-3β signaling, driving angiogenesis via VEGF-A and HIF-1α upregulation .
Preclinical Models
-
Ovarian Cancer: FILIP1L overexpression in orthotopic mouse models reduced peritoneal metastases by 7–16 fold .
-
Colorectal Cancer: FILIP1L knockout mice exhibited colonic hyperplasia and mucin hypersecretion, mimicking human mucinous adenocarcinoma .
Clinical Relevance
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- FILIP1L inhibits progression in colorectal cancer by suppressing tumor cell proliferation and angiogenesis. PMID: 27750216
- Research has shown that FILIP1L expression is linked to the inhibition of metastases and chemoresistance in ovarian neoplasms. This effect is associated with the downregulation of epithelial-mesenchymal transition (EMT) through beta-catenin degradation. Notably, FILIP1L expression correlates with significantly improved overall survival. PMID: 27776341
- These findings suggest that FILIP1L reduces beta-catenin levels, which may lead to the transcriptional downregulation of Wnt target genes, such as matrix metalloproteinases (MMPs), resulting in the inhibition of metastasis. PMID: 24327474
- Downregulation of FILIP1L associated with DNA methylation is linked to the invasive phenotype in various cancers. PMID: 24340050
- These findings suggest that downregulation of FILIP1L associated with DNA methylation is related to the invasive phenotype in ovarian cancer. Modulation of FILIP1L expression holds potential as a target for ovarian cancer therapy. PMID: 21693594
- Research has identified a novel function for FILIP-1L and a pathway for Hsf1 degradation through the ubiquitin-proteasome system. PMID: 21784850
- DOC1 may play a role in mediating some of the effects of EMAP-II on endothelial cells. PMID: 15935955
